RxDoctor Payments Data

John Jones, MD

Family Medicine · Chamberlain, SDNPI 1275586265

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.8% of the total across 91 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Lilly USA, LLC at 26.3% of the total.

$1,520in general payments, 2019–2025

Across 91 payments — averaging $16.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$401
  • Amgen$362
  • Sanofi-aventis U.S. LLC$125
  • Astellas Pharma US Inc$109
  • Novartis$105
  • Pfizer$78
  • plus $341 from 12 others

What the payments were for

  • Food & beverage$1,42594%
  • Education$956%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,520 in reported general payments places this provider in the 85th percentile of 408 family medicine providers in South Dakota.

See all family medicine providers in South Dakota

Medicare billing

Part B allowed, 2024
$17,355
Medicare patients
69
Services billed
275

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban49$30,457
RybelsusSemaglutide22$28,183
OzempicSemaglutide27$27,260
MounjaroTirzepatide25$25,188
Alosetron Hcl13$20,421
JanuviaSitagliptin Phosphate18$18,039
XareltoRivaroxaban11$15,324
JardianceEmpagliflozin14$12,396
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$11,119
Spiriva RespimatTiotropium Bromide17$8,299
LinzessLinaclotide14$7,983
DuleraMometasone/Formoterol13$7,270
Colesevelam Hcl16$4,892
OxycontinOxycodone Hcl11$3,457
Albuterol Sulfate HfaAlbuterol Sulfate73$1,769

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$67$55,44349 claims
PfizerEliquis$78$30,45749 claims
Lilly USA, LLCMounjaro, Olanzapine$401$26,26174 claims
MerckJanuvia, Dulera$30$25,30931 claims
Boehringer IngelheimJardiance, Spiriva Respimat$31$20,69531 claims
Johnson & JohnsonXarelto$18$15,32411 claims
AbbVieLinzess$19$7,98314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 408 family medicine providers in South Dakota.

Other family medicine in Chamberlain

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →